Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

American journal of respiratory and critical care medicine - 1 Dec 2017

Kelly Elizabeth A, Esnault Stephane, Liu Lin Ying, Evans Michael D, Johansson Mats W, Mathur Sameer, Mosher Deane F, Denlinger Loren C, Jarjour Nizar N

Abstract excerpt

RATIONALE: Mepolizumab, an IL-5-blocking antibody, reduces exacerbations in patients with severe eosinophilic asthma. Mepolizumab arrests eosinophil maturation; however, the functional phenotype of eosinophils that persist in the blood and airway after administration of IL-5 neutralizing antibodies has not been reported. OBJECTIVES: To determine the effect of anti-IL-5 antibody on the numbers and phenotypes of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Asthma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Bronchi

Share to Bronchoalveolar Lavage Fluid

Share to Enzyme-Linked Immunosorbent Assay

Share to Eosinophils

Share to Respiratory System

Source

Open in PubMed Open full text

Identifiers

PMID: 28862877
DOI: 10.1164/rccm.201611-2234OC
PMCID: PMC5736971

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.PMID 28862877Read ↗

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic PhenotypeSemantic proximity Read ↗

Monitoring eosinophils to guide therapy with Biologics in Asthma: does the compartment matter?Semantic proximity Read ↗

Lessons learned from targeting eosinophils in human disease.Semantic proximity Read ↗

The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic AsthmaSemantic proximity Read ↗

Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotypeSemantic proximity Read ↗

Reslizumab in the treatment of severe eosinophilic asthma: an update.Semantic proximity Read ↗

Mepolizumab for COPD with Eosinophilic Phenotype following HospitalizationSemantic proximity Read ↗

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic.Semantic proximity Read ↗

Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen ChallengeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.